SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Provectus Pharmaceuticals Inc.
PVCT 0.0720+2.9%Oct 31 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Howard Williams6/4/2015 11:45:21 AM
1 Recommendation

Recommended By
Jack Russell

  Read Replies (1) of 13111
 
One of these days, "SOMEBODY" is going to develop ...... or be recognized as having ....... an ablative immunotherapy drug that is highly efficacious in treating solid tumors and:

1) It requires no assessment of patients' gene defects.

2) One off-the-shelf formulation can be used to treat all patients.

3) It has insignificant side effects.

4) It can be administered to all accessible tumors on an outpatient basis.

5) It has a low production cost and is easy to store and transport.

Mark my words: you can count on this happening.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News